Jefferies Initiates Kite Pharma At Buy

Analysts at Jefferies initiated coverage on shares of Kite Pharma KITE with a Buy rating. The target price for Kite Pharma is set to $35. Kite Pharma's shares gained 1.95% to close at $24.05 yesterday.